• EN - English
  • HR - hrvatski
  • IT - italiano
Parliamentary question - E-001933/2022(ASW)Parliamentary question

    Answer given by Ms Kyriakides on behalf of the European Commission

    The Commission and the European Centre for Disease Prevention and Control (ECDC) are closely monitoring the epidemiological situation regarding the outbreak of monkeypox virus and following up on evidence regarding transmission and health risks[1].

    On 23 May 2022, ECDC has published a Rapid Risk assessment: Monkeypox multi-country outbreak[2]; and since then is providing regular epidemiological updates on the situation, the latest dated 15 June 2022[3].

    ECDC has published Interim advice on Risk Communication and Community Engagement during the monkeypox outbreak in Europe[4].

    The document is intended for use by health authorities providing advice on the communication of risks and for the engagement of population groups based on the outbreak’s epidemiological characteristics, recommending preventive measures and encouraging healthcare seeking behaviours to facilitate early detection and notification of cases.

    It has also assessed, through the Health Emergency Preparedness and Response Authority (HERA), the Member States’ needs of medical countermeasures such as vaccines, antivirals and personal protective equipment.

    Based on the needs identified, HERA has directly purchased vaccines against monkeypox[5] for Member States[6] and is working on a joint procurement for the only antiviral approved in the EU (Tecovirimat), in which 28 Member States are interested.

    Last updated: 3 August 2022
    Legal notice - Privacy policy